{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T04:28:17Z","timestamp":1782448097134,"version":"3.54.5"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T00:00:00Z","timestamp":1712880000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T00:00:00Z","timestamp":1712880000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-024-01049-z","type":"journal-article","created":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T11:02:09Z","timestamp":1712919729000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Like a bridge over troubled water: keeping the myeloma down en route to CAR-T"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0274-0585","authenticated-orcid":false,"given":"Joshua","family":"Richter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,12]]},"reference":[{"key":"1049_CR1","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/jha2.335","volume":"3","author":"ST Bhaskar","year":"2022","unstructured":"Bhaskar ST, Dholaria BR, Sengsayadeth SM, Savani BN, Oluwole OO. Role of bridging therapy during chimeric antigen receptor T cell therapy. EJHaem. 2022;3:39\u201345.","journal-title":"EJHaem"},{"key":"1049_CR2","doi-asserted-by":"publisher","unstructured":"Afrough A, Hashmi H, Hansen D, Sidana S, Ahn C, Peres L, et al. Real-World Impact of Bridging Therapy on Outcomes of Ide-cel for Myeloma in the U.S. Myeloma Immunotherapy Consortium. Blood Cancer J. 2023. https:\/\/doi.org\/10.21203\/rs.3.rs-3477431\/v1","DOI":"10.21203\/rs.3.rs-3477431\/v1"},{"key":"1049_CR3","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1200\/OP.22.00315","volume":"18","author":"J Mikhael","year":"2022","unstructured":"Mikhael J, Fowler J, Shah N. Chimeric antigen receptor T-cell therapies: barriers and solutions to access. JCO Oncol Pr. 2022;18:800\u20137.","journal-title":"JCO Oncol Pr"},{"key":"1049_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2023.109933","volume":"189","author":"HS Ababneh","year":"2023","unstructured":"Ababneh HS, Yee AJ, Raje NS, Martin S, Frigault MJ, Ng AK, et al. Radiation therapy as a bridging and salvage strategy in patients with relapsed or refractory multiple myeloma undergoing BCMA-targeted CAR T-cell therapy. Radiother Oncol. 2023;189:109933. https:\/\/doi.org\/10.1016\/j.radonc.2023.109933.","journal-title":"Radiother Oncol"},{"key":"1049_CR5","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.ijrobp.2019.05.065","volume":"105","author":"AJ Sim","year":"2019","unstructured":"Sim AJ, Jain MD, Figura NB, Chavez JC, Shah BD, Khimani F, et al. Radiation therapy as a bridging strategy for CAR T cell therapy with axicabtagene ciloleucel in diffuse large B-cell lymphoma. Int J Radiat Oncol Biol Phys. 2019;105:1012\u201321.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1049_CR6","doi-asserted-by":"publisher","first-page":"259.e1","DOI":"10.1016\/j.jtct.2022.12.021","volume":"29","author":"H Hubbeling","year":"2023","unstructured":"Hubbeling H, Silverman EA, Michaud L, Tomas AA, Shouval R, Flynn J, et al. Bridging radiation rapidly and effectively cytoreduces high-risk relapsed\/refractory aggressive B cell lymphomas prior to chimeric antigen receptor T cell therapy. Transpl Cell Ther. 2023;29:259.e1\u2013259.e10.","journal-title":"Transpl Cell Ther"},{"key":"1049_CR7","doi-asserted-by":"publisher","first-page":"504.e1","DOI":"10.1016\/j.jtct.2023.05.016","volume":"29","author":"A Zafar","year":"2023","unstructured":"Zafar A, Huang C-Y, Lo M, Arora S, Chung A, Wong SW, et al. Intensity of cyclophosphamide-based bridging therapy before chimeric antigen receptor T cell therapy in myeloma. Transpl Cell Ther. 2023;29:504.e1\u2013504.e7.","journal-title":"Transpl Cell Ther"},{"key":"1049_CR8","doi-asserted-by":"publisher","first-page":"2871","DOI":"10.1182\/bloodadvances.2020001837","volume":"4","author":"CC Pinnix","year":"2020","unstructured":"Pinnix CC, Gunther JR, Dabaja BS, Strati P, Fang P, Hawkins MC, et al. Bridging therapy prior to axicabtagene ciloleucel for relapsed\/refractory large B-cell lymphoma. Blood Adv. 2020;4:2871\u201383.","journal-title":"Blood Adv"},{"key":"1049_CR9","first-page":"01745","volume":"S2666-6367","author":"OS Akhtar","year":"2023","unstructured":"Akhtar OS, Modi K, Kim J, Skelson L, Smith E, Al-Jumayli MA, et al. Simple score of albumin and CRP predicts high-grade toxicity in patients with multiple myeloma receiving CAR-T therapy. Transpl Cell Ther. 2023;S2666-6367:01745\u20131.","journal-title":"Transpl Cell Ther"},{"key":"1049_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1169071","volume":"14","author":"Y Liu","year":"2023","unstructured":"Liu Y, Jie X, Nian L, Wang Y, Wang C, Ma J, et al. A combination of pre-infusion serum ferritin, CRP and IL-6 predicts outcome in relapsed\/refractory multiple myeloma patients treated with CAR-T cells. Front Immunol. 2023;14:1169071. https:\/\/doi.org\/10.3389\/fimmu.2023.1169071.","journal-title":"Front Immunol"},{"key":"1049_CR11","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1182\/blood-2023-177749","volume":"142","author":"D Pan","year":"2023","unstructured":"Pan D, Mouhieddine TH, Fu W, Moshier E, Parekh S, Jagannath S, et al. Outcomes after CAR T cells in multiple myeloma patients with extramedullary and paramedullary disease. Blood. 2023;142:1006.","journal-title":"Blood"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01049-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01049-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01049-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T11:02:40Z","timestamp":1712919760000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01049-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,12]]},"references-count":11,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1049"],"URL":"https:\/\/doi.org\/10.1038\/s41408-024-01049-z","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,12]]},"assertion":[{"value":"30 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Joshua Richter receives an honorarium from advisory boards and consulting from BMS.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"64"}}